Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
August 15, 2016 11:48 AM EDTBTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and CD101 update.
Analyst Timothy Chiang commented, We expect more visibility on the Co.s novel echinocandin (antifungal) product candidate, CD101, by early 2017 when... More
Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
August 15, 2016 8:19 AM EDTNeedham & Company reiterated a Buy rating and $20.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the release of company's 2Q16 financial results and management updates. The Phase 2 non-inferiority STRIVE trial of IV CD101 in Candidemia (NCT02734862) is expected to enroll 90 patients, randomized 1:1:1 to standard... More
